SQUAMOUS CELL EA3202

Study #EA3202

A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent / Metastatic Head and Neck Cancers